Stock SBS STRATEC SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Stratec SE

Equities

SBS

DE000STRA555

Advanced Medical Equipment & Technology

Market Closed - Xetra
Other stock markets
 11:35:07 2024-04-26 am EDT 		5-day change 1st Jan Change
41.65 EUR +3.74% Intraday chart for Stratec SE +3.74% -8.56%
Apr. 26 STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating ZD
Apr. 26 STRATEC BIOMEDICAL SYSTEMS AG : Warburg Research remains Neutral ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 733.5 1,485 1,669 983.7 553.7 506.3 - -
Enterprise Value (EV) 1 810.8 1,567 1,705 983.7 520.2 643.3 582 567.5
P/E ratio 45.5 x 59.3 x 42 x 33.8 x 42.6 x 36.5 x 19.6 x 18.9 x
Yield 1.38% 0.73% 0.69% - 1.21% 2.31% 2.18% 2.38%
Capitalization / Revenue 3.31 x 5.94 x 5.81 x 3.58 x 2.11 x 1.84 x 1.71 x 1.57 x
EV / Revenue 3.66 x 6.27 x 5.94 x 3.58 x 1.99 x 2.33 x 1.96 x 1.76 x
EV / EBITDA 19.8 x 30.2 x 25.6 x 16.8 x 12.5 x 12.8 x 9.59 x 8.34 x
EV / FCF 159 x 90.7 x 39.4 x - 46.9 x 20.4 x 15 x 16.5 x
FCF Yield 0.63% 1.1% 2.54% - 2.13% 4.91% 6.68% 6.06%
Price to Book 4.61 x 8.61 x 8.12 x - 2.37 x 2.09 x 1.96 x 1.82 x
Nbr of stocks (in thousands) 12,025 12,090 12,111 12,130 12,156 12,156 - -
Reference price 2 61.00 122.8 137.8 81.10 45.55 41.65 41.65 41.65
Announcement Date 4/2/20 3/31/21 3/30/22 3/28/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 221.6 250.1 287.3 274.6 261.9 275.6 296.6 322.8
EBITDA 1 40.85 51.98 66.61 58.58 41.58 50.09 60.66 68.02
EBIT 1 31.15 41.71 54.27 45.05 27.07 38.8 38.54 44.75
Operating Margin 14.05% 16.68% 18.89% 16.41% 10.34% 14.08% 12.99% 13.86%
Earnings before Tax (EBT) 1 18.32 33.02 46.83 39.09 18.23 19.35 29.9 35.22
Net income 1 14.44 25.18 39.96 29.22 13.07 13.87 25.83 26.84
Net margin 6.52% 10.07% 13.91% 10.64% 4.99% 5.03% 8.71% 8.32%
EPS 2 1.340 2.070 3.280 2.400 1.070 1.141 2.126 2.198
Free Cash Flow 1 5.115 17.28 43.24 - 11.08 31.6 38.85 34.37
FCF margin 2.31% 6.91% 15.05% - 4.23% 11.46% 13.1% 10.65%
FCF Conversion (EBITDA) 12.52% 33.24% 64.92% - 26.66% 63.08% 64.04% 50.52%
FCF Conversion (Net income) 35.42% 68.63% 108.22% - 84.82% 227.86% 150.41% 128.04%
Dividend per Share 2 0.8400 0.9000 0.9520 - 0.5500 0.9621 0.9089 0.9914
Announcement Date 4/2/20 3/31/21 3/30/22 3/28/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 111.3 75.39 61.81 137.2 70.46 60.48 64.53 62.67 74.23 50.87
EBITDA 23.51 - - - - - - - - -
EBIT 1 18.43 15.04 6.141 21.18 - 3.816 - - 10.85 3.145
Operating Margin 16.56% 19.95% 9.94% 15.44% - 6.31% - - 14.62% 6.18%
Earnings before Tax (EBT) - - - - - - - - - -
Net income - - - - - - - - - -
Net margin - - - - - - - - - -
EPS - - - - - - - - - -
Dividend per Share - - - - - - - - - -
Announcement Date 4/2/20 5/5/22 8/10/22 8/10/22 11/3/22 4/28/23 9/5/23 10/28/23 3/28/24 4/26/24
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 77.3 82.7 36.6 - - 137 75.7 61.2
Net Cash position 1 - - - - 33.5 - - -
Leverage (Debt/EBITDA) 1.891 x 1.591 x 0.5491 x - - 2.736 x 1.247 x 0.9002 x
Free Cash Flow 1 5.12 17.3 43.2 - 11.1 31.6 38.9 34.4
ROE (net income / shareholders' equity) 9.28% 15.2% 21.1% - 7.29% 9.21% 11% 12.4%
ROA (Net income/ Total Assets) 5.03% 7.98% 11.4% - 3.87% 3.01% 4.73% 5.76%
Assets 1 287.3 315.7 350.2 - 337.9 460.4 545.9 465.7
Book Value Per Share 2 13.20 14.30 17.00 - 19.20 19.90 21.30 22.90
Cash Flow per Share 2 1.760 2.620 5.210 - 1.600 2.980 3.860 3.410
Capex 1 16.1 14.6 20.2 - 17.4 18.8 19.1 19.3
Capex / Sales 7.29% 5.83% 7.04% - 6.65% 6.83% 6.45% 5.99%
Announcement Date 4/2/20 3/31/21 3/30/22 3/28/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Stratec SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
41.65 EUR
Average target price
43.33 EUR
Spread / Average Target
+4.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
STRATEC SE Stock Stratec SE
-8.56% 541M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. SBS Stock
  4. Financials Stratec SE